Aslan Pharmaceuticals Ltd (ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ASLN Nasdaq 8731 http://aslanpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aslan Pharmaceuticals Ltd (ADR

ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Mar 28th, 2023 11:00 am
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Mar 24th, 2023 11:00 am
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference - Mar 22nd, 2023 11:00 am
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year? - Mar 20th, 2023 1:40 pm
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Mar 14th, 2023 11:00 am
ASLAN Pharmaceuticals Limited's (NASDAQ:ASLN) recent 25% pullback adds to one-year year losses, hedge funds owners may take drastic measures - Mar 13th, 2023 11:54 am
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change - Mar 10th, 2023 12:00 pm
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now - Mar 9th, 2023 2:55 pm
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata - Mar 8th, 2023 12:00 pm
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year? - Mar 2nd, 2023 2:40 pm
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata - Feb 28th, 2023 12:00 pm
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M - Feb 24th, 2023 11:00 am
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients - Feb 24th, 2023 10:59 am
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies - Jan 3rd, 2023 12:00 pm
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC - Dec 22nd, 2022 4:34 pm
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis - Dec 19th, 2022 6:53 pm
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences - Dec 16th, 2022 12:00 pm
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients - Dec 15th, 2022 12:00 pm
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference - Nov 21st, 2022 12:00 pm
Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus - Nov 10th, 2022 7:17 pm